B. Riley Expects Reduced Earnings for Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Stock analysts at B. Riley lowered their Q3 2025 earnings per share estimates for shares of Eton Pharmaceuticals in a research note issued to investors on Thursday, May 15th. B. Riley analyst M. El-Saadi now forecasts that the company will post earnings per share of $0.10 for the quarter, down from their prior forecast of $0.11. B. Riley has a "Buy" rating and a $26.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' FY2027 earnings at $1.91 EPS, FY2028 earnings at $2.29 EPS and FY2029 earnings at $2.52 EPS.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The company had revenue of $17.28 million for the quarter, compared to the consensus estimate of $14.33 million.

A number of other equities analysts have also commented on the company. HC Wainwright restated a "buy" rating and set a $33.00 price objective on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th. Craig Hallum raised their target price on Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a "buy" rating in a report on Wednesday, May 14th.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock traded down $0.44 during mid-day trading on Monday, reaching $19.81. 271,640 shares of the company were exchanged, compared to its average volume of 196,984. The company has a fifty day simple moving average of $15.31 and a 200-day simple moving average of $14.28. Eton Pharmaceuticals has a 12 month low of $3.18 and a 12 month high of $21.48. The firm has a market cap of $531.26 million, a PE ratio of -90.05 and a beta of 1.22.

Institutional Investors Weigh In On Eton Pharmaceuticals

Large investors have recently modified their holdings of the business. AlphaQuest LLC acquired a new stake in shares of Eton Pharmaceuticals in the 1st quarter valued at $53,000. Tower Research Capital LLC TRC acquired a new stake in shares of Eton Pharmaceuticals in the 4th quarter valued at $86,000. Quantbot Technologies LP acquired a new stake in shares of Eton Pharmaceuticals in the 1st quarter valued at $101,000. Jefferies Financial Group Inc. acquired a new stake in shares of Eton Pharmaceuticals in the 4th quarter valued at $133,000. Finally, Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Eton Pharmaceuticals by 18.3% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock valued at $141,000 after purchasing an additional 1,634 shares in the last quarter. Institutional investors and hedge funds own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.